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Objective: To identify preoperative clinical features that predict a durable improvement in renal function with renal artery
stenting (RAS).
Methods: Sixty-one patients with renal insufficiency (serum creatinine >1.5 mg/dL) underwent RAS for renal salvage.
Patients were categorized as “responders” if estimated glomerular filtration rate (eGFR) at last follow-up was improved
20% or more over baseline. Patients with stable or worse renal function after RAS were labeled “non-responders.” For the
purpose of calculating changes in eGFR, patients on dialysis were represented by an eGFR of 10 ml/min/1.73 m2. Renal
volume was estimated as kidney length  width  depth/2.
Results: The median age of the cohort was 66 years (interquartile range [IQR], 60-73 years). Median preoperative serum
creatinine was 1.8 mg/dL (IQR, 1.6-2.3), and median estimated glomerular filtration rate (eGFR) was 34 mL/min/
1.73 m2 (IQR, 24-45). With stenting, 17 of 61 patients (27.9%) derived a durable improvement in renal function at a
median follow-up of 24 months (IQR, 16-33 months). The largest proportion of stented patients (44.3%) had no
improvement in renal function after stenting, while a subset (27.9%) experienced a decline in renal function. Responders
enjoyed a 47% improvement in renal function from baseline, while non-responders had a 13% decrement in renal function
(P< .0001). Responders had a higher baseline serum creatinine, lower eGFR, and a steeper decline in renal function prior
to RAS, compared with non-responders. Kidney length, width, depth, and volume were not significantly different
between responders and non-responders. Logistic regression analysis identified the rate of decline of renal function prior
to stenting as the only independent preoperative predictor of improved renal function after RAS (odds ratio, 3.4; 95%
confidence interval, 1.6 to 7.5; P  .0019). The rate of decline in eGFR per week was more than 20-fold greater for
responders than non-responders (2.1% vs 0% decline in eGFR per week; P < .0001). No predictors of renal function
deterioration after stenting were identified.
Conclusions: The current study found that a steep decline in preoperative renal function portends a higher likelihood of
renal salvage from RAS among patients with renal insufficiency. Incorporating this finding into patient selection may
improve outcomes for RAS. (J Vasc Surg 2011;54:1414-21.)
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uSurgical revascularization of the renal arteries for isch-
emic nephropathy is associated with improved renal func-
tion in 43% to 80% of patients.1-4 Moreover, retrieval of
renal function after surgical revascularization has been as-
sociated with improved dialysis-free survival.1 However,
the benefits of surgical revascularization for ischemic ne-
phropathy are achieved at considerable risk to the patient.
Centers of expertise have reported mortality rates ranging
from 4% to 7% for surgical revascularization for ischemic
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1414ephropathy,1,2 whereas the nationwide mortality rate for
enal artery bypasses performed for ischemic nephropathy is
t least two-fold higher (18%).5
Renal artery stenting (RAS) offers a lower risk alterna-
ive to surgical revascularization, but the response of renal
unction to RAS has been inferior to surgical revasculariza-
ion. In three recent series, improved renal function after
AS was observed in a minority (23%-50%) of patients.6-8
e surmise that the poor results for RAS are related to
atient selection. Currently, there is a relative dearth of
vidence-based guidelines to aid clinicians with patient
election for RAS. We hypothesize that there are clinical or
enal morphologic features that discriminate patients who
ill benefit from RAS (“responders”) from those who gain
o benefit from the procedure (“non-responders”). Thus,
he purpose of this study was to identify preoperative
linical features that predict a durable improvement in renal
unction with RAS.
ETHODS
Study population and clinical data collection. This
etrospective review reports the outcomes for patients with
enal insufficiency (serum creatinine 1.5 mg/dL) who
nderwent primary RAS at the University of Texas South-
estern Medical School and its affiliated hospitals over a
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Volume 54, Number 5 Modrall et al 14159-year period ending July 1, 2008. Inclusion required a
minimum of one month of postoperative follow-up and
two serial visits for laboratory testing to determine the
response of renal function to RAS. Exclusion criteria in-
cluded nonatherosclerotic pathologies and secondary le-
sions after prior stenting. Seventy-four patients with a
serum creatinine 1.5 mg/dL underwent RAS during the
study period. Thirteen patients were excluded due to insuf-
ficient pre- or postoperative clinical and laboratory data for
analysis (n  12) or concurrent nephrotoxicity (n  1),
leaving a cohort of 61 patients for analysis. The study was
approved by the Institutional Review Boards of the Univer-
sity of Texas Southwestern Medical School and the Dallas
Veterans Affairs Medical Center.
Demographic, clinical, renal morphologic, and proce-
dural data were collected. Average values for serum creati-
nine (mg/dL) and estimated glomerular filtration rate
(eGFR) at pre- and postoperative time points were calcu-
lated from two to three clinic visits. The abbreviated Mod-
ification of Diet in Renal Disease formula was used to
calculate eGFR: 186 x (serum creatinine)1.154 x
(age)0.203 x (0.742 if female) x (1.210 if African Ameri-
can).9 To permit calculations related to eGFR, patients
requiring renal replacement therapy were designated as
having an eGFR of 10 mL/min/1.73 m2. Average blood
pressure (BP) and numbers of antihypertensivemedications
were quantified as described previously.10
Definition of renal function response. The primary
outcome measure was renal function response to RAS.
Patients were categorized as “responders” if the average
eGFR at last follow-up was increased 20% over pre-
stenting eGFR, which is based on the American Heart
Association Reporting Guidelines and prior publica-
tions.6,7,11 Patients with stable (20% change in eGFR) or
worsened renal function (20% decrease in eGFR) after
RAS were designated “non-responders” and analyzed as
one group. A minimum of 1 month of follow-up was
required for inclusion to permit stabilization of renal func-
tion after stenting.
Kidney morphometrics. Kidney morphometrics were
obtained from preoperative contrast-enhanced computed
tomography (CT) or magnetic resonance (MR) angiogra-
phy. Prehydration was prescribed routinely prior to con-
trast-enhanced imaging, while pretreatment with muco-
myst or bicarbonate infusion was employed selectively.
Kidney measurements included pole to pole length, medial
to lateral width, and anterior to posterior depth. Dupli-
cate measurements were averaged for each kidney. Renal
volume was estimated from these parameters [(kidney
length)  (width)  (depth/2)], as validated and re-
ported previously.10,12,13
Statistical analysis. The primary end point of the
study was renal function response to RAS. Categorical data
were analyzed using 2 or Fisher exact tests. Continuous
data were reported as medians and interquartile ranges
(IQR). Comparisons of continuous data between groups
were performed with Wilcoxon matched pairs tests and
Mann-Whitney U tests. Stepwise multivariate logistic re- dression analysis was used to identify predictors of renal
unction response to stenting. Those variables that were
ignificant (P .05) on univariate analysis were included in
he regression model. Survival was calculated according to
he Kaplan-Meier technique, and survival curves were com-
ared using the log-rank test. For all statistical analyses, the
hreshold for significance was .05. Statistical analysis was
erformed using SAS, version 9.13 (SAS Institute, Inc,
ary, NC).
ESULTS
Baseline characteristics. The study population con-
isted of 61 patients with a median age of 66 years (IQR,
0-73 years). Baseline characteristics (Table I) were typical
f a patient population with advanced atherosclerosis. The
ohort had moderate baseline renal insufficiency with a
edian serum creatinine of 1.8 mg/dL (IQR, 1.6-2.3
g/dL), excluding patients receiving renal replacement
herapy. The median eGFR was 34 mL/min/1.73 m2
IQR, 23-45 mL/min/1.73 m2). Four patients (6.6%)
ere receiving renal replacement therapy prior to RAS.
rior to RAS, declining renal function was apparent in the
ohort. The median change in preoperative eGFR was
0.46% per week, over a median preoperative interval of 9
eeks (IQR, 6-14 weeks).
Three patients (4.9%) had solitary kidneys due to prior
ephrectomy. All patients had concurrent hypertension
ith a median preoperative systolic BP of 149 mm Hg
IQR, 140-179 mm Hg) and median diastolic BP of 75
m Hg (IQR, 67-89 mmHg) on a median of four antihy-
ertensive medications (IQR, 3-5 medications).
Procedural details. Seventy-six renal arteries were
tented in 61 patients (46 unilateral, 15 bilateral). One
rocedural complication was reported, consisting of a dis-
laced stent that required endovascular extraction. Stented
esions had a median stenosis of 80% (IQR, 70%-88%) by
rteriography. Embolic protection was employed in a mi-
ority of cases (n  2). Predilatation of the stenosis was
equired in 14 patients (23.0%) prior to stenting. All im-
lanted stents were balloon expandable stents with a me-
able I. Baseline cohort characteristics (n  61)
isk factor Patients, no. (%)
ge 66 years (60-73)
ale gender 35 (57.4)
ace
White 40 (65.6)
African-American 12 (19.7)
Hispanic/Other 9 (14.7)
ypertension 61 (100)
iabetes 25 (41.9)
oronary artery disease 38 (62.3)
yperlipidemia 25 (41.0)
obacco history 56 (91.8)
hronic obstructive pulmonary disease 14 (23.0)
or age, data are presented as median (interquartile range).ian stent diameter of 6 mm (IQR, 5-6 mm) and length of
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employed.
Cohort outcomes. The median follow-up for the co-
hort was 24 months (IQR, 16-33 months). Outcomes for
the entire cohort, analyzed in aggregate, are outlined in
Table II. As a group, renal function was not significantly
improved by RAS. Of the four patients receiving renal
replacement therapy prior to stenting, one was liberated
from hemodialysis and three remained on dialysis. Five
additional patients with stage V chronic kidney disease
(median preoperative eGFR of 16 mL/min/1.73 m2;
IQR, 13-19) ultimately proceeded to dialysis during
follow-up.
Despite a lack of improvement in renal function for the
cohort, BP was significantly improved by RAS (Table II).
Both the median systolic and diastolic BP were significantly
improved after stenting, and fewer antihypertensive medi-
cations were required for BP control.
Three patients were diagnosed with in-stent stenosis
based on follow-up renal artery imaging at a median inter-
val of 10 months (IQR, 7-10 months) post-stenting. None
of the patients with restenosis experienced any change in
renal function or BP control due to the restenosis and
underwent prophylactic angioplasty to treat the radio-
graphic finding.
Patient-specific outcomes. Although the cohort at
large derived no improvement in renal function from RAS,
a subset of 17 patients (27.9%) had a substantial improve-
ment in eGFR over baseline after stenting. These patients
were deemed “responders,” according to our criteria. Non-
responders consisted primarily of patients with no signifi-
cant change in their eGFR (n 27), although a subset (n
17) had worsened renal function after RAS. For respond-
ers, themedian improvement in eGFR after stenting was 13
mL/min/1.73 m2 (IQR, 10 to 18mL/min/1.73 m2),
whereas non-responders had a small decrease in eGFR
(3.0 mL/min/1.73 m2; IQR 9 to 0 mL/min/1.73
m2) at late follow-up. Compared with baseline, these
changes represent a 47% improvement in eGFR for re-
sponders and a 13% decrement in eGFR for non-responders
(P .0001). Although the proportion of patients requiring
renal replacement therapy at late follow-up was higher
among non-responders (18.2%) than responders (nil), this
difference was not statistically significant (P  .09). The
Table II. Cohort outcomes after renal artery stenting (n 
Parameter Preo
Serum creatinine (mg/dL)a 1.8 (1
eGFR (mL/min/1.73 m2) 34 (2
Proportion on dialysis (%)
Systolic blood pressure, mm Hg 149 (1
Diastolic blood pressure, mm Hg 75 (6
No. of antihypertensive medications 4 (3
eGFR, Estimated glomerular filtration rate.
aExcluding patients receiving renal replacement therapy.
Cohort data are analyzed in aggregate. Data are presented as medians (interenal function response to stenting proved to be durable, as to early responders suffered sufficient deterioration in renal
unction to be recategorized as non-responders at late
ollow-up. In addition, long-term survival was not signifi-
antly different between responders and non-responders
Fig 1).
A major focus of the analysis was identifying preopera-
ive parameters that may distinguish responders from non-
esponders and aid in patient selection. To that end,
esponders and non-responders were compared with uni-
ariate analyses (Table III). Two major differences in re-
ponders and non-responders were identified. Responders
ad worse renal function at baseline, based on both serum
reatinine and eGFR. Responders also had a steeper decline
n renal function over the weeks prior to stenting. Indeed,
he rate of decline of preoperative eGFR per week was
0-fold more precipitous among responders than non-
esponders (Table III; P  .0001). No other demographic
r clinical factors differed significantly between responders
nd non-responders (Table III).
Forty-three of 61 patients (70.5%) had sufficient pre-
perative renal imaging to permit measurements of renal
orphology. Within the subset of patients with preopera-
ive imaging, kidney length, width, depth, and volume for
)
ive Postoperative P valuea
.3) 1.8 (1.5-2.2) .14
) 34 (25-46) .58
13.1 .36
79) 132 (121-145) .0001
) 68 (61-77) .0001
3 (2-4) .01
ile ranges) and compared with Wilcoxon matched pairs test.
ig 1. The Kaplan-Meier plot depicts survival after renal artery
tenting for responders (continuous line) and non-responders (dis-
ontinuous line). Ticks along the lines represent censored cases.
he number at risk is provided for each time point. The standard
rror for responders and non-responders exceeded 10% at 78 and
08 months, respectively. There was no significant difference in
urvival between the two groups (log-rank test, P  .35).61
perat
.6-2
4-45
6.6
40-1
7-89
-5)he ipsilateral (stented) kidneys and contralateral (un-
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Volume 54, Number 5 Modrall et al 1417stented) kidneys were no different between responders and
non-responders (Table III). Of note, the proportion of
patients receiving intravenous contrast for preoperative im-
aging was not significantly different between the responder
and non-responder groups (58.8% vs 75%; P  .23).
The subset of patients with worsened renal function
(20% decline in eGFR) after RAS was also examined for
features to distinguish this group from other patients un-
dergoing stenting. This analysis failed to identify demo-
graphic, clinical, or renal morphologic differences between
patients with worsened renal function and the remainder of
the cohort (Table IV, online only).
Procedural details were examined for potential dif-
ferences between responders and non-responders. The pro-
portion of bilateral stenting procedures was higher among
non-responders (27.3%) than responders (17.7%), but the
difference was not significant (P  .52). The severity of
renal artery stenosis prior to RAS was not different
between responders (80%; IQR, 70-90%) and non-re-
sponders (78%; IQR, 70-82%; P  .08). Median stent
diameter was similar between the two groups (respond-
ers vs non-responders  6 mm [IQR, 5-6 mm] vs 6 mm
[IQR, 5-6 mm]; P  .60), and stent length was identical
(18 vs 18 mm; P  .66).
Multivariate analysis was used to identify independent
predictors of a favorable response of renal function to RAS.
The two variables that were significant on univariate anal-
ysis, preoperative serum creatinine and rate in decline in
preoperative renal function, were included in the multivar-
Table III. Comparison of preoperative clinical parameters
after renal stenting
Preoperative parameter Improved renal
(n  17
Age (years) 64 (58-72)
Gender (% males) 52.9%
Race
White 64.7%
African-American 11.8%
Other 23.5%
Diabetes 35.3%
Serum creatinine (mg/dL)a 2.1 (1.8-2.7
eGFR (mL/min/1.73 m2) 29 (20-38)
Percent decline in eGFR per week (IQR) 2.1 (3.8 to
Preoperative dialysis (%) 5.9%
Solitary kidney (%) 0%
Bilateral stenting 17.7%
Kidney length (cm)b 9.6 (9.3-10.
Kidney width (cm)b 5.3 (4.5-6.7
Kidney depth (cm)b 5.0 (4.6-5.6
Ipsilateral kidney volume (cm3)b 119 (102-14
Contralateral kidney volume (cm3)b 115 (58-194
Systolic BP, mm Hg (IQR) 160 (136-18
Diastolic BP, mm Hg (IQR) 75 (69-98)
No. of BP medications (IQR) 3.0 (3.0-4.5
BP, Blood pressure; eGFR, estimated glomerular filtration rate; IQR, interq
aExcluding patients receiving renal replacement therapy.
bKidney morphometrics data calculated from the 43 of 61 patients with pre
Cohort data are analyzed in aggregate. Data are presented as medians (inteiate model. Logistic regression analysis identified the rate of 0ecline of renal function prior to stenting as the only
ndependent predictor of improved renal function after
AS (odds ratio, 3.4; 95% confidence interval, 1.6-7.5;
 .0019). There was no significant interaction between
he two independent variables in the model. The C statistic
or the model was .88, indicating an excellent ability to
iscriminate responders from non-responders. The Hos-
er-Lemeshow goodness-of-fit test for themodel was non-
ignificant (P  .11), indicating little departure from a
erfect fit.
The relationship between the rate of change in preop-
rative renal function and outcome for RAS is depicted in
ig 2. Responders experienced a precipitous drop in eGFR
ver a median time interval of 12 weeks (IQR, 9-17 weeks)
rior to stenting (Fig 2, A). In contrast, non-responders
ad no deterioration in in eGFR over a median of 9 weeks
IQR, 6-12 weeks) before RAS (Fig 2, B). From these data,
e sought to identify a potential threshold slope in preop-
rative eGFR that could be used in patient selection for
AS. Using the median change in preoperative eGFR per
eek for the entire cohort (0.46% per week) as a mini-
um threshold for patient selection for stenting would
ave correctly identified responders in 15 of 17 cases (Fig
). However, 15 of 44 non-responders (34.1%) also had a
ate of decline in renal function that exceeded this thresh-
ld (Fig 3). The sensitivity and specificity for this threshold
ere 0.88 and 0.66, respectively. The positive predictive
alue was 0.50, while the negative predictive value was
atients with and without improvement in renal function
ion Unchanged/worsened renal function P value
(n  44)
67 (60-74) .56
59.1% .78
.37
65.9%
22.7%
11.4%
43.2% .77
1.7 (1.6-2.2) .02
39 (28-46) .03
0) 0.0 (0.8-1.4) .0001
7.3% .89
6.8% .55
27.3% .52
9.9 (8.9-10.5) .81
5.4 (5.1-5.9) .21
5.1 (4.7-5.7) .70
129 (107-173) .34
134 (95-161) .80
146 (141-177) .65
75 (66-88) .68
4.0 (3.0-5.0) .61
range.
tive renal imaging.
ile ranges) and compared with Wilcoxon matched pairs test.for p
funct
)
)
1.
1)
)
)
8)
)
6)
)
uartile.94.
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In our experience, only one in four patients with renal
insufficiency enjoyed improved renal function at late
follow-up after RAS. This outcome is sobering, but not
surprising in view of the lack of specific guidelines to direct
patient selection for RAS. The 2005 American College of
Cardiology/American Heart Association (ACC/AHA)
Practice Guidelines stated that “percutaneous revascular-
ization is reasonable for patients with [renal artery stenosis]
and progressive chronic kidney disease with bilateral [renal
artery stenosis] or [a renal artery stenosis] to a solitary
kidney.”14 The ACC/AHA guidelines further stated that
RAS “may be considered for patients with [renal artery
stenosis] and chronic renal insufficiency with unilateral
[renal artery stenosis].”14 For clinicians at the bedside,
these guidelines are too non-specific to be helpful clinically
in patient selection. The goal of the current study was to
compare and contrast “responders” with “non-respond-
Fig 2. The decrease in preoperative eGFR prior to renal artery
stenting is shown for responders (A), and non-responders (B).
Values represent medians with interquartile ranges. The difference
in slopes of the two lines was significant (P  .0001).ers” to identify predictors of outcome that may facilitate satient selection. Our data showed that the rate of decline
n preoperative renal function is a robust predictor of the
esponse of renal function to RAS. Responders had a 20-
oldmore precipitous decline in preoperative renal function
han non-responders (Fig 2, Table III), which translated
ostoperatively into a durable recovery of renal function for
esponders.
Taking these results a step further, we sought to iden-
ify a threshold rate of decline in preoperative renal function
hat could be used in patient selection. Using the median
hange in preoperative eGFR over time in our study pop-
lation (0.46% per week) as a threshold would have been
dentified 15 of 17 responders correctly. However, 15 of 44
on-responders also had a decline in renal function that
xceeded this threshold. The greater utility of this thresh-
ldmay lie in identifying those patients whowill not benefit
rom RAS. The high negative predictive value (0.94) of this
hreshold suggests that 94% of patients with a decline in
reoperative eGFR lower than this threshold (ie, less rapid
eterioration in renal function), will see little or no im-
rovement in renal function after RAS. Although further
alidation of this threshold is required, we believe this
riterion may have utility in patient selection. These data
lso suggest that longitudinal assessments of renal function
re critical to patient selection for RAS, rather than basing
atient selection for RAS on a single “snapshot” in time.
The relationship between decline in preoperative renal
unction and outcomes for renal artery revascularization is
ot a new concept. Dean and colleagues found that patients
ith more rapid deterioration in renal function prior to
ig 3. This scatterplot shows the preoperative change in eGFR
er week for responders and non-responders. For each group, the
edian and interquartile range is displayed. The dotted horizontal
ine represents the median for the entire cohort.urgical revascularization of the renal arteries were more
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Volume 54, Number 5 Modrall et al 1419likely to experience an increase in eGFR after surgery.15 In
their analysis of the Cleveland Clinic experience with RAS
for renal salvage, Kashyap et al reported a similar observa-
tion in a cohort of stented patients.8 Neither Dean nor
Kashyap proposed a threshold rate of change in preopera-
tive eGFR for use in patient selection, which we believe
would be particularly useful for clinicians.
Bilateral revascularization and unilateral revasculariza-
tion of solitary kidneys were identified previously as clinical
parameters that may portend a greater probability of re-
trieval of renal function, but the data are conflicting. Dean
found that bilateral revascularization was strongly associ-
ated with improved renal function after surgical renal artery
revascularization.15 Kashyap found no association between
bilateral RAS and outcome in his series.8 Our observations
echoed Kashyap’s observations, as the 15 patients in our
series who underwent bilateral stenting were non-responders.
Patients undergoing bilateral stenting constituted a small
minority (24.6%) in our series, so it remains unclear
whether bilateral treatment is a predictor of outcome
for RAS.
The proportion of renal function responders in the
current series deserves comment. Twenty-seven percent of
patients in our series were renal function responders, which
is at the lower end of the spectrum of previously reported
response rates.6-8 This discrepancy may be explained, in
part, by differences in the definition of a clinical response
and the duration of outcome. For instance, 42% of patients
were categorized as responders in Kashyap’s series, but that
study utilized a more liberal definition of renal function
response (10% improvement in eGFR) to define respond-
ers. Edwards reported that 50% of 26 patients treated for
renal salvage had a 20% improvement in eGFR over
baseline, but those data represent short-term outcomes
assessed at 4 to 6 weeks postoperatively. By comparison,
the current study reported late outcomes at a median
follow-up of 24 months. Nolan reported a response rate of
23% at 1-year post-stenting,6 which is more consistent with
the results from the current study.
It is noteworthy that the predictor of renal function
response identified in this study differs from those identi-
fied in our prior study on BP response to RAS.10 In that
study, we identified three predictors of a favorable BP
response to stenting: (1) use of 4 antihypertensive med-
ications; (2) preoperative diastolic BP 90 mm Hg; and
(3) preoperative clonidine use. None of these variables was
a predictor of renal function response in the current study.
This finding suggests that different variables impact the
outcome for RAS, depending on the clinical presentation
for renovascular disease. It is important for clinicians to be
cognizant of these differences when selecting patients
for RAS.
Although the results of the current study confirm and
extend observations from prior studies, there are limitations
to the study that must be acknowledged. First, the current
study cannot address the potential role of renal stenting in
“stabilizing” renal function of some non-responders since
there is no control group of patients with untreated renalrtery stenosis for comparison. Second, preoperative duplex-
erived resistive indexes have been used in some studies to
tratify responders and non-responders,16 but those data
ere not available for the majority of patients in this series.
s such, we cannot compare the relative predictive power of
esistive indexes to the predictor identified in this study.
hird, the lack of a comprehensive program of postopera-
ive duplex surveillance in this series precluded an objective
ssessment of stent patency for the cohort. However, no
arly responders suffered sufficient deterioration in renal
unction on serial laboratory testing to be re-categorized as
on-responders at late follow-up. This observation could
e interpreted as evidence that any lack of renal function
esponse in non-responders was unlikely to be a conse-
uence of in-stent stenosis. Fourth, the use of an embolic
rotection device is a technical adjunct that may prevent
arenchymal embolization during renal artery stenting and
mprove outcomes.7,17 Embolic protection was not used in
he majority of cases in the current series, which could
xplain the higher proportion of patients experiencing a
eterioration in renal function post-stenting, compared
ith other studies.7 Finally, the small size of this series
imited the statistical power of the analyses, which may have
ompromised our ability to identify other predictors of
enal function response.
ONCLUSIONS
The current study found that a minority (27.9%) of
atients responded to RAS with an improvement in renal
unction. A steep decline in preoperative renal function
ortends a higher likelihood of renal salvage from RAS
mong patients with renal insufficiency. We propose a
hreshold rate of decline in preoperative eGFR of 0.46%
er week to discriminate responders from non-responders,
lthough this threshold requires validation in a different
atient population. If validated, incorporating this finding
nto patient selection may improve the outcomes for RAS.
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DrMatthew S. Edwards (Winston-Salem, NC). Goodmorn-
ing. I would like to first congratulate Dr Modrall and his team on
another excellent presentation regarding renovascular disease
and to thank the Society for the privilege of initial discussion. Dr
Modrall has presented today a series of 43 patients undergoing
renal artery stenting with extended follow-up who also had CT or
MRI data allowing for parenchymal volume estimation. This re-
port examines the predictors of renal function improvement and
follows up their previous work currently in press at the Journal of
Vascular Surgery examining blood pressure responses. In this
study, only 23% of patients undergoing renal artery stent place-
ment experienced a 20% or greater increase in estimated glomeru-
lar filtration rate (eGFR) that was durable at a median follow-up of
26 months. Interestingly, an identical number of patients experi-
enced renal function that was worsened over the same interval.
Patients who experienced a significant improvement in their renal
function were more likely to have impaired renal function pre-
intervention. An increased rate of decline in renal function preop-
eratively was demonstrated to be the only significant predictor of a
subsequent, significant poststenting increase in eGFR. These data
confirm prior reports in the open surgical literature by Dr Dean
from our group and by other investigators in the stenting arena.
Dr Modrall and his group sought to define clinically useful
predictors of renal function improvement post renal stenting,
which represents a laudable goal in this clinical area, as renal
function improvement has been repeatedly shown to be one of, if
not the most, important predictor of improved survival following
renal revascularization therapy. This study is also quite timely in
discussing the topic of suboptimal patient selection for renal stent-
ing given the recent negative results from two randomized trials of
such therapy, ASTRAL, and STAR. Most vascular surgeons are
well aware that a subset of patients receive tremendous benefit
from renal revascularization and appreciate the difficulty in predict-
ing such responses. It is almost certain that the negative results of
the clinical trials previously mentioned are, at least in part, due to
the inclusion of significant numbers of patients unlikely to benefit.roup for their efforts. With that being said, I do have several
uestions for Dr Modrall.
First, as an investigator of this same issue, our group at Wake
orest is currently focusing on trying to identify the kidney that is
amaged beyond the capacity for a large vessel revascularization to
esult in significant functional improvement. As we all know,
iabetes is a leading cause of “medical” kidney disease and diabetes
ffected 40% of the patients in your report. I did not see it listed in
he covariates examined as a potential predictor of significant renal
unction response. Did your group examine diabetes in this way,
nd, if so, what were the results?
Second, how many eGFR measures did you employ to define
he rate of renal function decline? Was your measure a linearized
easure of two points or a slope of multiple data points?
Third, in your manuscript, you suggest that your results are
omewhat atypical (on the low side) as far as renal function
esponse rates. They are actually perfectly consistent with weighted
verages across the literature that we employ in our funding
pplications with an observed rate of improvement and deteriora-
ion of 25%. Given the importance of renal function response to
ollow-up survival, did your group also analyze predictors of sig-
ificant renal function deterioration during follow-up?
Fourth, your presentation detailed the finding that bilateral
ntervention was not a predictor of significant renal function re-
ponse, refuting the previous work by Dr Dean and the findings
with regards to blood pressure) of the Scottish Newcastle group.
id you consider unilateral treatment to a solitary kidney bilateral
reatment? Could you offer any thoughts on the lack of an effect
bserved for global renal revascularization? Furthermore, how did
ou deal with kidney volumes in a patient with two treated kidneys
s far as using the data to predict renal function response?
Fifth, you present data with a median follow-up of 26 months
nd lasting response rate of 23%.What was the short-term response
ate? Your presentation reported a very low rate of restenosis and
o renal function or blood pressure effect in those patients. What
as the observed fall-off rate in initial positive renal function
esponse?
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Volume 54, Number 5 Modrall et al 1421Finally, were you able to examine other potential predictive
modalities such as renal duplex derived resistive index or measures
of glomerular damage such as urinary albuminuria in your sample?
Congratulations, again, on your excellent presentation and I
look forward to your answers.
Dr J. Gregory Modrall. Thank you, Dr Edwards, for your
comments and your insightful questions. I can’t say enough about
the contributions you and your group have made to this field, and
I’m humbled to have you as a discussant.
In looking at the covariates, you correctly identified diabetes
as a variable that we should have reported in our presentation.
Diabetics were equally distributed between the responder and
non-responder groups, so it appears that diabetes is not a predictor
of response to renal artery stenting.
Your question regarding the technique for quantifying preop-
erative estimated GFR is important. For that analysis, we examined
two time points for each patient–late pre-op and remote pre-op
time points. For each time point, a minimum of twomeasurements
of estimated GFR were used to calculate an average eGFR for that
time point. For simplicity of reporting, we did not report the eGFR
at intervals between these time points to plot a curve.
Your question about searching for predictors of significant
renal function deterioration is also very important. You correctly
point out that it is probably just as important to identify predictors
of a failure to respond to stenting as it is to identify predictors of a
favorable response. Unfortunately, we simply did not orient our
analysis in that direction, but that’s something we will add to the
manuscript.
iWith regard to your question of how we handled those pa-
ients who had solitary kidneys, there were only two patients in the
ntire series that had a prior nephrectomy. With so few patients, it
as apparent that these cases had minimal influence on the results
egardless of how they were analyzed.
As for the statistical approach to incorporating kidney volumes
or patients who underwent bilateral stenting into the analysis,
here was no need for mixed modeling to incorporate both patient
evel and kidney level data into the multivariate analysis because
idney volume was not significant on univariate analysis. I will add,
hough, that the results did not differ based on whether an average
f the two kidneys or individual kidney volumes were used in the
nalysis, as kidney volume was not a significant predictor in univar-
ate analysis.
With regard to your question about the early versus late
esponse rates, there were no early responders who then subse-
uently became non-responders based on late deterioration of
enal function. This suggests that renal function responses to renal
rtery stenting are durable, and also suggests that there was no
linically significant restenosis that were not captured with postop-
rative clinical and radiologic follow-up.
Finally, with regard to resistive indicies and glomerular dam-
ge manifesting as albuminuria, this omission should be acknowl-
dged as a major shortcoming of this study. Many of our patients
ere referred from elsewhere with duplex sonography results and
roceeded directly to a secondary imaging study, so those data are
ncomplete and uninterpretable.
Again, I thank you for your insightful questions.
operative renal imaging.
rquartile ranges) and compared with Wilcoxon matched pairs test.
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November 20111421.e1 Modrall et alTable IV (online only). Comparison of preoperative clin
renal function after renal stenting
Preoperative parameter Worsened renal
(n  17
Age (years) 66 (59-72
Gender (% males) 52.9%
Race
White 58.8%
African-American 29.4%
Other 11.8%
Diabetes 41.2%
Serum creatinine (mg/dL)a 2.0 (1.6-3.
eGFR (mL/min/1.73 m2) 32 (19-45
Percent decline in eGFR per week (IQR) 0.0 (1.1-
Preoperative dialysis (%) 0%
Solitary kidney (%) 5.9%
Bilateral stenting 23.5%
Kidney length (cm)b 9.2 (8.9-9.
Kidney width (cm)b 5.3 (4.6-5.
Kidney depth (cm)b 5.1 (4.6-5.
Ipsilateral kidney volume (cm3)b 119 (102-1
Contralateral kidney volume (cm3)b 119 (85-17
Systolic BP, mm Hg (IQR) 133 (134-1
Diastolic BP, mm Hg (IQR) 69 (65-91
No. of BP medications (IQR) 4.0 (3.0-5.
BP, Blood pressure; eGFR, estimated glomerular filtration rate; IQR, interq
Continuous data are presented as medians (interquartile ranges, IQR) and c
aExcluding patients receiving renal replacement therapy.
bKidney morphometrics data calculated from the 43 of 61 patients with pre
Cohort data are analyzed in aggregate. Data are presented as medians (inteical parameters for patients with and without deterioration in
function Unchanged/improved renal function P value
) (n  44)
) 67 (61-73) .51
59.1% .78
1.0
68.2%
15.9%
15.9%
40.9% .77
2) 1.8 (1.6-2.2) .49
) 38 (27-45) .57
1.0) 0.67 (1.6-0.44) .28
9.1% .57
4.5% 1.0
25.0% 1.0
6) 10.0 (9.1-10.5) .13
4) 5.5 (5.1-6.0) .07
3) 5.0 (4.8-5.7) .57
48) 129 (107-173) .34
9) 138 (85-175) .78
91) 153 (140-178) .59
) 75 (69-88) .38
0) 3.0 (3.0-4.0) .08
uartile range.
ompared with Mann-Whitney U test.
